NCT07090954View on ClinicalTrials.gov

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2030

Conditions
Multiple Myeloma
Interventions
DRUG

GR1803 injection

Participants will receive GR1803 injection.

DRUG

Anti-CD38 Monoclonal Antibody

Participants will receive anti-CD38 monoclonal antibody.

Trial Locations (2)

Unknown

Shanghai Fourth People's Hospital Affiliated with Tongji University, Shanghai

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY

NCT07090954 - A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | Biotech Hunter | Biotech Hunter